A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
This clinical trial is an 'extension study' for adults who have solid cancer tumours. It is designed for people who have already taken part in an earlier research study using the targeted cancer drug pertuzumab (also known as Perjeta). In this study, participants can continue their treatment with pertuzumab, given through a drip into a vein. It may be given on its own or alongside other cancer medicines, such as trastuzumab (Herceptin). Because patients have already been using the drug, the main purpose of this study is to provide ongoing access to treatment while checking its long-term safety. The research team will track any side effects people experience and monitor how well the cancer is kept under control over time. Joining is completely voluntary, and doctors will carefully supervise all care.
At a glance
What is this study about?
When people take part in a clinical trial for cancer, an experimental medicine might work well for them. However, trials eventually end. This study is an 'extension study', which means it acts as a bridge. It allows people with solid cancer tumours who benefited from an earlier pertuzumab trial to carry on receiving their treatment safely.
Pertuzumab (Perjeta) is a targeted cancer drug. Rather than affecting all fast-growing cells like standard chemotherapy does, it works by attaching to specific proteins on cancer cells to stop them growing and dividing. In this study, it may be given on its own or combined with another targeted drug called trastuzumab (Herceptin). Both drugs are given as an infusion, which means they enter the bloodstream directly through a small tube in a vein.
While patients continue their therapy, doctors will closely monitor their health. The main goal is to record any side effects—both mild and serious—to build a clearer picture of the medicine's long-term safety. The study also tracks how long the treatment keeps the cancer from growing, helping researchers learn more about how to use these drugs effectively in the future.
Key takeaways
- Designed for people who previously took pertuzumab in an earlier trial.
- Provides ongoing access to pertuzumab, alone or with other cancer therapies.
- Mainly focuses on tracking long-term safety and side effects.
- Involves regular hospital visits for infusions, health checks, and scans.
- Participation is voluntary, and you can stop taking part at any time.
Who may be eligible?
This study is open to adults aged 18 and over who have a solid cancer tumour. Men and women are both eligible to take part.
To be able to join, you must have already been enrolled in an earlier trial of pertuzumab sponsored by the pharmaceutical company Roche. Your doctor must also believe that continuing with pertuzumab is still safe, appropriate, and potentially helpful for your condition.
People who have not previously taken part in one of these specific pertuzumab trials will not be able to join this study. Your hospital care team can check your medical records to confirm if your previous trial qualifies.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with a solid cancer tumour.
- I took part in an earlier Roche-sponsored clinical trial for pertuzumab.
- My cancer doctor agrees that continuing pertuzumab is a suitable option for me.
What does participation involve?
If you take part, you will receive pertuzumab as an intravenous infusion (a drip into your arm or chest) at your hospital clinic, usually every few weeks. Depending on your specific treatment plan, you may also receive other cancer medicines, such as trastuzumab, at the same visits.
At each hospital visit, the care team will check your general health, carry out routine blood tests, and ask you about any side effects or new symptoms. You will also have regular scans, such as CT or MRI scans, to see how your tumour is responding.
You can generally stay in the study and continue receiving the medicine for as long as your cancer remains stable and you do not experience troublesome side effects. You can also choose to leave the study at any point.
Potential risks and benefits
Locations (3)
- —UnverifiedPortugal
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What is an extension study?
It is a study that allows patients who finished an earlier clinical trial to keep receiving the treatment while researchers gather more long-term safety information.
How is the study medicine given?
Pertuzumab is given as a liquid drip into a vein, usually through a small needle in your arm or through a central line, during a hospital visit.
Will I have to pay for the study treatment?
No, clinical trial medicines are provided free of charge by the study sponsor.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time and for any reason. Your normal medical care will not be affected.
What happens if my cancer gets worse?
If scans show your cancer is growing or if you have severe side effects, your doctor will discuss stopping the trial and starting a different treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.